Straits Times Index
3,283.07 +17.12 (+0.52%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,429.18 +47.83 (+0.57%) Bitcoin USD
62,903.85 +1,482.17 (+2.41%) CMC Crypto 200
1,304.87 -53.14 (-3.91%)
Axsome Therapeutics, Inc. (AXSM)
After hours:
| Previous close | 75.68 |
| Open | 76.06 |
| Bid | 73.59 x 200 |
| Ask | 73.87 x 400 |
| Day's range | 73.65 - 76.56 |
| 52-week range | 55.02 - 98.40 |
| Volume | |
| Avg. volume | 748,708 |
| Market cap | 3.499B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Axsome Therapeutics to Present at Upcoming Investor Conferences
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabu
- GlobeNewswire
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract executed with second large group purchasing organization (GPO) for potential coverage of Auvelity Positive pivotal Phase 3 trial results of AXS-12 in narcolepsy announced Topline results of ADVANCE-2 Phase 3 trial
- GlobeNewswire
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Mental Health America, during May’s Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living wit
